MedTrace Logo

Propel Drug-Eluting Sinus Stent Family Open Cohort

NCT05925985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 215

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of this study is to confirm the long-term clinical safety and performance, acceptability of identified risks, and to detect emerging risks based on factual evidence for the PROPEL family of products when used according to labeling (in patients with chronic rhinosinusitis (CRS) undergoing sinus surgery). Additionally, this study intends to collect data on use of corticosteroid-eluting implants in the European CRS population. Data collected will be used to ensure continued consistency between clinical data, the information materials supplied by the manufacturer, and the risk management documentation.

Conditions

  • Chronic Rhinosinusitis (Diagnosis)

Interventions

OTHER

NA-Observational Registry

NA Observational Registry

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-02-19
Completion
2025-09-01
FDA Device
Yes

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05925985 on ClinicalTrials.gov